Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.12, read 2026-10-29
Ethical passes the values gate
Price23.44 USD
Fair value25.95
Ethical score70.0/100
Our investment reviews on this name
2026-10-26Read Accumulation23.97-2.2% to today Markdown gives way to Accumulation
2026-10-02Read Markdown23.63-0.8% to today ✓Distribution gives way to Markdown after a 6% slide in 11 days
2026-09-21Read Distribution25.02-6.3% to today ✓Markup gives way to Distribution after a 13% slide in 4 weeks
2026-08-21Read Markup28.64-18.2% to today Distribution gives way to Markup after a 42% rise in 7 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Artivion, Inc. holds its Accumulation at $23.44. The statistical read favours the sellers, held for 96 days.
As held on the ledger · 2026-10-29
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 96 days
Price at the screen
$23.44
Valuation
N/A trailing · 32.03 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.22
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
29.12%
Below 33%
Interest-bearing debt is just 29.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
17.48%
Below 49%
Money owed to the company is 17.5% of assets, under the 49% limit.
Pass
Revenue purity
0.17%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Artivion, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 29%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AORT's ethical verdict changes
Today AORT passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-29 screen. The gold marker is the market price at the same screen. A 10.7% margin of safety to the base estimate.
Third-party analyst targets: 9 covering, consensus Strong Buy. The average target sits +71% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-29 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Heart valves alone do not make a bargain
Picture a surgeon fitting an On-X valve into a patient. The procedure saves a life, yet the business behind it earns just three pence on every pound of sales while returning only three percent on equity. Artivion grows revenue at eighteen percent, yet trades at thirty-five times forward earnings with an unknown competitive moat. Those figures leave no margin for error once growth slows.
We pass because the seventeen percent gap between the twenty-five dollar share price and our twenty-nine dollar fair value does not compensate for thin profitability and an elevated multiple. Analyst targets sit higher, yet our screen finds nothing compelling once the low returns and high valuation are weighed together. Ethical clearance removes one objection but creates no investment case on its own.
Low margins leave little room for execution slips or reimbursement pressure, and an unknown moat offers scant protection if larger device makers expand. The combination keeps the opportunity rating at none despite the clean ethical screen. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AORT trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-30Accumulation$23.44+2.2%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$22.94-4.3%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 9.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42. Since the last review it its composite score eased.
2026-10-19Markdown$21.87+2.9%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42.
2026-10-12Markdown$21.26-10.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42. Since the last review it its composite score rose.
2026-10-02Markdown · changed$23.63-5.6%Entry 8
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 12.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42.
2026-08-21Markup · changed$28.64+14.3%Entry 6
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42.
2026-07-21Distribution$25.06+24.7%Entry 5
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 24.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42.
2026-07-18Distribution$20.10+0.0%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.